Utility of combination external beam radiation with LuPSMA for patient management: a case series analysis
S Mohammadi, I Pompa, V Haberman, B Kako, M White… - 2024 - Soc Nuclear Med
242159 Introduction: LuPSMA (177Lu-vipivotide tetraxetan) is an effective therapy for
metastatic castration-resistant prostate cancer (mCRPC), providing systemic radiation …
metastatic castration-resistant prostate cancer (mCRPC), providing systemic radiation …
Implementation outcomes of a multidisciplinary approach for Lu177-PSMA-617 therapy.
M Nedrud, J Wang, V Maldonado Grijalva, C Kelleher… - 2024 - ascopubs.org
80 Background: Lu177-PSMA-617 (LuPSMA) is a recently approved treatment for patients
with metastatic castration resistant prostate cancer (mCRPC). Successful treatment in real …
with metastatic castration resistant prostate cancer (mCRPC). Successful treatment in real …
Real world outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT).
CP Bergstrom, H Song, SM Ruiz, J Chien, K Moore… - 2024 - ascopubs.org
86 Background: Lu177-PVT is a novel radioligand, which was recently approved by the FDA
to treat mCRPC. Real world data on its use and efficacy is limited. We aimed to build a new …
to treat mCRPC. Real world data on its use and efficacy is limited. We aimed to build a new …
Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Interim results of a phase II trial.
SK Sandhu, JA Violet, J Ferdinandus, SP Thang… - 2018 - ascopubs.org
5040 Background: Lutetium-177 (177Lu)-PSMA617 (LuPSMA) is a radiolabelled small
molecule that binds with high affinity to prostate specific membrane antigen (PSMA) …
molecule that binds with high affinity to prostate specific membrane antigen (PSMA) …
Lutetium-177–PSMA-617 experience in Appalachian patients with advanced prostate cancer at West Virginia University Health Science Center.
SL Yu, S Holler, S Wen, X Wang, TF Hogan - 2024 - ascopubs.org
e17045 Background: Lutetium Lu-177 vipivotide tetraxetan (Lu-177) allowed for improved
biochemical and radiographic response rate with relatively low toxicity for metastatic …
biochemical and radiographic response rate with relatively low toxicity for metastatic …
[HTML][HTML] Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA
Background: Progressive metastatic castrate-resistant prostate carcinoma (mCRPC) is a
highly lethal condition. Lutetium-177 (177 Lu)-PSMA617, a radiolabelled small molecule …
highly lethal condition. Lutetium-177 (177 Lu)-PSMA617, a radiolabelled small molecule …
Results of a 50 patient single-center phase II prospective trial of Lutetium-177 PSMA-617 theranostics in metastatic castrate-resistant prostate cancer.
228 Background: Lutetium-177 (177Lu)-PSMA-617 (LuPSMA) is a radiolabelled small
molecule that binds with high affinity to prostate specific membrane antigen (PSMA) …
molecule that binds with high affinity to prostate specific membrane antigen (PSMA) …
[HTML][HTML] The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation …
Background Isolated local failure (ILF) can occur in patients who initially receive definitive
radiation therapy for prostate cancer. Salvage therapy for ILF includes high dose rate (HDR) …
radiation therapy for prostate cancer. Salvage therapy for ILF includes high dose rate (HDR) …
[HTML][HTML] 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during …
F Alongi, M Rigo, V Figlia, F Cuccia, N Giaj-Levra… - Radiation …, 2020 - Springer
Abstract Background Unity Elekta is a unique magnetic resonance (MR)-linac that
conjugates a 1.5 Tesla MR unit with a 7 MV flattening filter free accelerator. A prospective …
conjugates a 1.5 Tesla MR unit with a 7 MV flattening filter free accelerator. A prospective …
[HTML][HTML] Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu] Lu-PSMA-617 for prostate cancer-from bench to …
D Arbuznikova, A Klotsotyra, L Uhlmann… - Theranostics, 2024 - ncbi.nlm.nih.gov
Management of prostate cancer (PC) might be improved by combining external beam
radiotherapy (EBRT) and prostate-specific membrane antigen (PSMA)-targeted radioligand …
radiotherapy (EBRT) and prostate-specific membrane antigen (PSMA)-targeted radioligand …